Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors

Principal Investigator: Dai, Tong

A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer

Principal Investigator: Chatta, Gurkamal S

(COG ANBL1821) A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma

Principal Investigator: Twist, Clare J

Improving Host Factors in Patients with Monoclonal Gammopathies

Principal Investigator: Hillengass, Jens

A Phase II Study of cemiplimab, an anti-PD-1 monoclonal antibody, and ISA101b vaccine in patients with recurrent/metastatic HPV16 positive Oropharyngeal Cancer who have experienced disease progression with prior anti-PD-1 therapy

Principal Investigator: Dai, Tong

(COG #AGCT1532) Phase 3 Accelerated BEP Trial:A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Principal Investigator: Levine, Ellis G

(S2012) Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)"

Principal Investigator: Iyer, Renuka V

A PHASE 1/2 FEASIBILITY, SAFETY, AND ACTIVITY STUDY OF PSCA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR ENGINEERED T CELLS (BPX-601) IN SUBJECTS WITH PREVIOUSLY TREATED ADVANCED SOLID TUMORS

Principal Investigator: Chatta, Gurkamal S

A randomized, parallel-group open-label trial of ENDS users switching from flavors of potentially high-toxicity profile to flavors of potentially low-toxicity profile (CRoFT_3.2)

Principal Investigator: Goniewicz, Maciej L

A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies

Principal Investigator: Dy, Grace K

(A091902) A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naïve, and Nivolumab and Carbozantinb in Taxane Pretreated Subjects With Angiosarcoma

Principal Investigator: Gupta, Ajay

Acute GVHD Suppression using Costimulation Blockade to Expand Non-malignant Transplant (ASCENT)

Principal Investigator: Barth, Matthew J

A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO)

Principal Investigator: Fountzilas, Christos

Phase I, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with…

Principal Investigator: Wang, Eunice S

(PBTC-060) A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Principal Investigator: Twist, Clare J

A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination with
Endocrine Therapy in Patients Age 70 and Older with Hormone Receptor Positive
Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition

Principal Investigator: O'Connor, Tracey L

Phase 2, Open-Label Randomized Study of Daratumumab, carfilzomib, Lenalidomide, and Dexamethasone vs. Carfilzomib, Lenalidomide, and Dexamethasone vs. Bortezomib, Lenalidomide, and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)

Principal Investigator: Hillengass, Jens

CI-8993-101 Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients with Advanced Solid Tumor Malignancies

Principal Investigator: Fountzilas, Christos

A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer

Principal Investigator: Frederick, Peter

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies

Principal Investigator: Wang, Eunice S

A PHASE 1B/2 STUDY OF AVB-S6-500 IN COMBINATION WITH CABOZANTINIB, AVB-S6-500 IN COMBINATION WITH CABOZANTINIB AND NIVOLUMAB, AND AVB-S6-500 MONOTHERAPY IN PATIENTS WITH ADVANCED OR METASTATIC CLEAR CELL RENAL CELL CARCINOMA

Principal Investigator: George, Saby

NC762-01 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects with Advanced or Metastatic Solid Tumors

Principal Investigator: Zsiros, Emese

(ANBL1531) A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma

Principal Investigator: Twist, Clare J

(APEC1621D) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF LY3023414 IN PATIENTS WITH SOLID TUMORS

Principal Investigator: Twist, Clare J

(ACNS1723) A Phase 2 Study of Dabrafenib (NCS#763760) with Trametinib (NCS# 763093) after Local Irradiation in Newly-Diagnosed BRAFv600-Mutant High-Grade Glioma (HGG) (IND#145355)

Principal Investigator: Twist, Clare J